KYONGBO PHARMACEUTICAL CO., LTD.
Founded in 1987, Kyongbo Pharmaceutical is an API specialist producing cephalosporin antibiotics like ceftriaxone and developing ADC conjugation technology.
As of 2026-10-10, KYONGBO PHARMACEUTICAL CO., LTD. has 1 Korean MFDS device approval, 255 Korean MFDS drug approvals, 2 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 1987 and listed on KOSPI in 2015, Kyongbo Pharmaceutical is a pharmaceutical company specializing in active pharmaceutical ingredients (APIs). Its API segment produces and exports cephalosporin antibiotics such as ceftriaxone and has developed proprietary ADC conjugation and payload-linker technology, while its finished-drug segment sells prescription products including Maxigesic injection, Vilda/Vildamet tablets, and the inhalation anesthetic Surgeon. In its Q4 2025 report, API revenue was KRW 133,833 million and finished-drug revenue KRW 126,485 million, for total revenue of KRW 264,104 million, and the company diversified into medical devices in 2018 and animal health in 2020.
Products & technology
- CeftriaxoneCephalosporin antibiotic API, exported domestically and overseas
- ADC conjugation / payload-linker technologyProprietary technology developed for entry into the ADC CDMO market
- Maxigesic InjectionCombination analgesic injection (finished drug)
- Vilda / Vildamet Tab.Finished drug product
- Surgeon Inhalation AnestheticInhalation anesthetic
- Rosuage Tab.Finished drug product
- Kyongbo Cefpodoxime Proxetil Tab.Antibiotic (finished drug)
Regulatory approvals
data.go.kr255 Korean MFDS drug approvals · 1994–2026 / 1 Korean MFDS device approvals · 2025
- MFDS drugTelmilopine S Tab. 40/5mg2026-08-19Drug · Prescription · Approval202602406
- MFDS drugTelmilopine S Tab. 40/2.5mg2026-08-19Drug · Prescription · Approval202602407
- MFDS drugTelmilopine S Tab. 80/2.5mg2026-08-06Drug · Prescription · Approval202602264
- MFDS drugTelmilopine S Tab. 80/5mg2026-08-06Drug · Prescription · Approval202602265
- MFDS drugVonokhan Tablet 20mg (Vonoprazan tosylate)2026-01-09Drug · Prescription · Approval202600067
- MFDS drugVonokhan10mg(Vonoprazan Tosylate)2026-01-09Drug · Prescription · Approval202600068
- MFDS drugKayglito Tab. 25/5mg(Empagliflozin, Linagliptinbesylate)2025-11-21Drug · Prescription · Approval202503048
- MFDS drugKayglito Tab. 10/5mg(Empagliflozin, Linagliptinbesylate)2025-11-21Drug · Prescription · Approval202503049
- MFDS drugEmpazamet tab. 12.5/500mg2025-11-18Drug · Prescription · Approval202502977
- MFDS drugEmpazamet tab. 12.5/850mg2025-11-18Drug · Prescription · Approval202502978
- MFDS drugEmpazamet12.5/850mg2025-11-13Drug · Prescription · Approval202502937
- MFDS drugEmpazamet tab. 5/1000mg2025-11-13Drug · Prescription · Approval202502938
Show 68 more
- MFDS drugEmpazamet tab. 5/500mg2025-11-12Drug · Prescription · Approval202502920
- MFDS drugEmpazamet tab. 5/850mg2025-11-12Drug · Prescription · Approval202502921
- MFDS drugEmpaza tab. 10mg2025-11-10Drug · Prescription · Approval202502902
- MFDS drugEmpaza tab. 25mg2025-11-10Drug · Prescription · Approval202502903
- MFDS drugJang & Q Capsule2025-07-31Drug · OTC · Notification202501999
- MFDSGlove, patient examination2025-04-25Product approval · Class 1수신 25-835 호
- MFDS drugGinef Tab. 2402024-08-27Drug · OTC · Notification202402065
- MFDS drugLirajenta Duo SR Tab. 2.5/1000mg2024-06-27Drug · Prescription · Approval202401557
- MFDS drugLirajenta Duo SR Tab. 5/1000mg2024-06-27Drug · Prescription · Approval202401558
- MFDS drugLirajenta Duo Tab. 2.5/1000mg2024-04-30Drug · Prescription · Approval202401040
- MFDS drugLirajenta Duo Tab. 2.5/850mg2024-04-30Drug · Prescription · Approval202401041
- MFDS drugLirajenta Duo Tab. 2.5/500mg2024-04-30Drug · Prescription · Approval202401042
- MFDS drugJoinchondro 800 Tab2024-04-26Drug · OTC · Notification202400995
- MFDS drugLirajenta Tab. 5mg2024-03-29Drug · Prescription · Approval202400690
- MFDS drugDAPAKHANMET XR Tab. 10/500mg2023-06-21Drug · Prescription · Approval202301896
- MFDS drugJANUSMET TAB. 50/850mg2023-03-13Drug · Prescription · Approval202300833
- MFDS drugJANUSMET TAB. 50/500mg2023-03-13Drug · Prescription · Approval202300834
- MFDS drugJANUSMET TAB. 50/1000MG2023-03-13Drug · Prescription · Approval202300835
- MFDS drugJanustinmet XR Tab. 50/1000mg2023-02-17Drug · Prescription · Approval202300581
- MFDS drugJanustinmet XR Tab. 50/500mg2023-02-17Drug · Prescription · Approval202300582
- MFDS drugJanustinmet XR Tab. 100/1000mg2023-02-17Drug · Prescription · Approval202300583
- MFDS drugJanustinDuo tab.10/100mg2023-01-30Drug · Prescription · Approval202300384
- MFDS drugDAPAKHANMET XR Tab. 10/1000mg2023-01-06Drug · Prescription · Approval202300146
- MFDS drugRyuma600power Tab2022-12-29Drug · OTC · Notification202204692
- MFDS drugRamokhan prefilled2022-11-07Drug · Prescription · Approval202204015
- MFDS drugVildamet tab 50/850mg2021-11-30Drug · Prescription · Approval202107713
- MFDS drugVildamet tab 50/500mg2021-11-30Drug · Prescription · Approval202107714
- MFDS drugVildamet tab 50/1000mg2021-11-30Drug · Prescription · Approval202107715
- MFDS drugPlatop gel2021-10-19Drug · OTC · Notification202107009
- MFDS drugVilda tab 50mg2021-09-10Drug · Prescription · Approval202106501
- MFDS drugMaxigesic Inj.2021-08-30Drug · Prescription · Approval202106243
- MFDS drugJolerone injection 5 mg/100mL(zoledronic acid monohydrate)2021-08-27Drug · Prescription · Approval202106203
- MFDS drugJanustin tab. 50mg2021-03-29Drug · Prescription · Approval202102719
- MFDS drugJanustin tab. 25mg2021-03-29Drug · Prescription · Approval202102720
- MFDS drugJanustin tab. 100mg2021-03-29Drug · Prescription · Approval202102721
- MFDS drugDAPAKHAN Tab. 10mg2021-02-08Drug · Prescription · Approval202101181
- MFDS drugKyongbo Cefprozil dry syrup2021-01-19Drug · Prescription · Notification202100550
- MFDS drugAtoeze tab 10/10mg2021-01-08Drug · Prescription · Approval202100233
- MFDS drugAtoeze tab 10/20mg2021-01-08Drug · Prescription · Approval202100234
- MFDS drugAtoeze tab 10/40mgRevoked2021-01-08Drug · Prescription · Approval202100235
- MFDS drugCANDEROVA Tab. 5/8mgRevoked2020-12-11Drug · Prescription · Approval202008711
- MFDS drugCANDEROVA Tab. 5/16mgRevoked2020-12-11Drug · Prescription · Approval202008712
- MFDS drugCANDEROVA Tab. 20/32mgRevoked2020-12-11Drug · Prescription · Approval202008713
- MFDS drugCANDEROVA Tab. 10/8mgRevoked2020-12-11Drug · Prescription · Approval202008714
- MFDS drugCANDEROVA Tab. 10/16mgRevoked2020-12-11Drug · Prescription · Approval202008715
- MFDS drugDexpanten tab 100mgRevoked2020-11-26Drug · OTC · Notification202008259
- MFDS drugPakis Tab.Revoked2020-09-21Drug · Prescription · Approval202006508
- MFDS drugBromel Tab. 45mg2020-09-03Drug · OTC · Notification202006143
- MFDS drugAldakill Tab.Revoked2020-07-27Drug · OTC · Notification202005446
- MFDS drugClasone CreamRevoked2020-06-29Drug · OTC · Notification202004716
- MFDS drugBenazole Cream2020-05-18Drug · OTC · Notification202003611
- MFDS drugTime-R SR Cap. 0.4mg2020-04-22Drug · Prescription · Approval202002885
- MFDS drugPencivir CreamRevoked2020-04-05Drug · Prescription · Notification202002379
- MFDS drugFamoton Tab. 20mg2020-03-18Drug · Prescription · Approval202001905
- MFDS drugBromel Enteric Coated Tab.Revoked2020-02-17Drug · OTC · Notification202001043
- MFDS drugUbican Cap.2020-02-04Drug · Prescription · Approval202000618
- MFDS drugApixol Tab. 5mg2020-01-31Drug · Prescription · Approval202000523
- MFDS drugApixol Tab. 2.5mg2020-01-31Drug · Prescription · Approval202000524
- MFDS drugWemebutine Tab. 150mg2019-11-20Drug · OTC · Notification201908017
- MFDS drugGinef Tab. 80mg2019-11-18Drug · OTC · Notification201907970
- MFDS drugGinef Tab.2019-11-18Drug · OTC · Notification201907971
- MFDS drugCandetan Tab. 16mg2019-11-14Drug · Prescription · Approval201907938
- MFDS drugCandetan Tab. 8mg2019-11-14Drug · Prescription · Approval201907939
- MFDS drugGel Cover Double Action SuspensionRevoked2019-11-12Drug · OTC · Notification201907880
- MFDS drugAlgit Sol.Revoked2019-10-21Drug · Prescription · Notification201907371
- MFDS drugK-Met SR Tab2019-09-26Drug · Prescription · Approval201906866
- MFDS drugNovaltan Tab. 10/160mg2019-09-25Drug · Prescription · Approval201906827
- MFDS drugTazopicin Inj. 2.25g2019-08-30Drug · Prescription · Notification201906207
Showing the 80 most recent of 256 records.
Clinical trials
data.go.kr28 MFDS clinical trial authorisations · 2012–2026 (Phase 1 15 · Bioequivalence 13)
- BioequivalenceKBP-RZ-262026-03-05
2 trial sites
- Phase 1KBP-25-01-A2025-10-20
1 trial site
- Phase 1보노칸정20밀리그램2024-09-10
1 trial site
- Phase 1K08-23-02-B2024-06-04
1 trial site
- Phase 1K08-23-02-B2024-05-02
1 trial site
- Phase 1K08-23-02-A2024-03-14
1 trial site
- Phase 1K08-23-02-A2024-02-05
1 trial site
- Phase 1K08-22-192023-09-21
1 trial site
- Phase 1K08-22-182023-09-21
1 trial site
- Phase 1경보리나글립틴메트포르민서방정(K08-22-06)2022-12-20
2 trial sites
- Phase 1경보리나글립틴메트포르민서방정(K08-22-06)2022-12-19
2 trial sites
- Phase 1경보리나글립틴메트포르민속방정(K08-22-07)2022-10-26
2 trial sites
Show 16 more
- Phase 1경보리나글립틴정2022-10-14
2 trial sites
- Bioequivalence노발탄정10/160밀리그램2021-08-27
2 trial sites
- Bioequivalence에이스틴정20밀리그램(아토르바스타틴칼슘수화물)2021-07-06
2 trial sites
- Bioequivalence수바스틴정(로수바스타틴칼슘)2021-07-06
2 trial sites
- Phase 1빌다메트정50/1000밀리그램 (KBP-702)2020-03-12
2 trial sites
- Phase 1빌다정50밀리그램 (KBP-701)2020-03-12
2 trial sites
- Bioequivalence세토렌세립(세프디토렌피복실)2019-03-06
2 trial sites
- Bioequivalence경보세프디토렌정(세프디토렌피복실)100밀리그램2018-10-30
2 trial sites
- Phase 1KB_RASA2018-04-23
1 trial site
- Bioequivalence경보세파클러캡슐2017-05-22
2 trial sites
- Bioequivalence경보오셀타미비르현탁용분말6mg/mL(오셀타미비르인산염)2017-01-11
2 trial sites
- Bioequivalence경보세푸록심악세틸정250밀리그램2016-02-03
2 trial sites
- Bioequivalence경보 타다라필정 20mg2014-05-20
2 trial sites
- Bioequivalence경보세파드록실수화물캡슐500밀리그램2013-11-27
2 trial sites
- Bioequivalence경보세푸록심악세틸정2012-08-13
- Bioequivalence경보세프프로질정(세프프로질수화물)2012-04-20
R&D and key agreements
Source: DART corporate disclosureADC 항암제 접합기술 및 Payload-Linker 기술 개발 · 항암 · Preparing entry into the global ADC CDMO market
Key disclosures
KRX KIND via OpenDARTPublications
PubMed · affiliation-matched- Corrigendum to "GPR41 and GPR43: From development to metabolic regulation" [Biomed. Pharmacother. 175 (2024) 116735].
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2024-10 · Lee DH, Kim MT, Han JH
- GPR41 and GPR43: From development to metabolic regulation.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2024-06 · Lee DH, Kim MT, Han JH
Patents
KIPRIS · applicant-matchedPublished · 2024-11 · Application 1020240157031
Published · 2024-10 · Application 1020240145145
Published · 2024-07 · Application 1020240095530
Published · 2024-07 · Application 1020240090341
Published · 2024-06 · Application 1020240083737
Published · 2024-01 · Application 1020240007353
Published · 2023-12 · Application 1020230174672
Published · 2023-12 · Application 1020230174673
Published · 2023-10 · Application 1020230139271
Registered · 2023-09 · Application 1020230127452
Show 51 more patents
Registered · 2023-09 · Application 1020230127451
CN · Published · 2023-07 · Application 202380067800.2
Published · 2023-07 · Application 1020230091998
Published · 2023-07 · Application 1020230087728
Published · 2023-06 · Application 1020230082934
Published · 2023-06 · Application 1020230077457
Rejected · 2022-10 · Application 1020220129048
Published · 2022-09 · Application 1020220120597
Withdrawn · 2022-08 · Application 1020220109115
Registered · 2022-06 · Application 1020220072906
Rejected · 2021-12 · Application 1020210178829
Withdrawn · 2021-09 · Application 1020210122953
Registered · 2021-07 · Application 1020210087156
Registered · 2021-04 · Application 1020210052453
Registered · 2021-04 · Application 1020210043155
Withdrawn · 2020-09 · Application 1020200113977
Withdrawn · 2020-06 · Application 1020200069178
Rejected · 2020-05 · Application 1020200053908
Withdrawn · 2020-05 · Application 1020200053235
Rejected · 2020-02 · Application 1020200017084
Registered · 2020-01 · Application 1020200012190
Rejected · 2019-12 · Application 1020190175926
Rejected · 2019-08 · Application 1020190099011
Withdrawn · 2019-02 · Application 1020190016613
Rejected · 2019-01 · Application 1020190000901
Withdrawn · 2018-12 · Application 1020180169551
Registered · 2018-11 · Application 1020180151340
Rejected · 2018-09 · Application 1020180113326
Rejected · 2018-05 · Application 1020180053065
Expired · 2018-04 · Application 1020180048617
Rejected · 2017-08 · Application 1020170104962
Registered · 2017-05 · Application 1020170058103
Registered · 2017-02 · Application 1020170024469
Registered · 2016-01 · Application 1020160004686
Expired · 2015-10 · Application 1020150149519
Registered · 2015-09 · Application 1020150126096
Rejected · 2015-02 · Application 1020150027772
Expired · 2015-02 · Application 1020150021559
Rejected · 2014-11 · Application 1020140163628
Registered · 2014-10 · Application 1020140132440
Withdrawn · 2014-07 · Application 1020140094704
Expired · 2014-07 · Application 1020140094029
Expired · 2014-07 · Application 1020140087416
Rejected · 2014-02 · Application 1020140016130
Expired · 2013-12 · Application 1020130152106
Rejected · 2013-06 · Application 1020130064010
EP · Registered · 2011-01 · Application 11000701.0
Rejected · 2010-07 · Application 1020100072991
Withdrawn · 2010-07 · Application 1020100068045
Rejected · 2009-05 · Application 1020090044171
Expired · 2003-11 · Application 1020030080495
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIOAI-SearchBot70
- MicrosoftBingbot2
- PerplexityPerplexityBot2
- AnthropicClaudeBot2
- GoogleGoogleOther1
Measured since Aug 27, 2026 · 5 AI engines · last read Oct 9, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for KYONGBO PHARMACEUTICAL CO., LTD. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies approved for the same productsPharma & CDMO
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
Founded in 1973, KOSDAQ-listed in 2001, Billions makes medical rubber products like condoms and runs an entertainment business.
KOSDAQ-listed lab equipment company manufacturing and distributing ultra-low temperature freezers, centrifuges, and autoclaves.
DIO Corporation, established in 1988 and listed on KOSDAQ in 2000, manufactures and sells dental implants.
Founded in 1982 and KOSDAQ-listed in 2008, Sewoon Medical manufactures medical aspirators and catheters/tubes.
Founded in 1964 and KOSPI-listed in 1991, Shinhung manufactures and distributes dental equipment and materials.
Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.
Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.
Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.
Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.
KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.
KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.
Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition